◢ TECHNICA.BIOBIOTECH ECOSYSTEM INTELLIGENCE
Polish Biotech Scene

Imagene.me

AI genome interpretation · Consumer & clinical genomics

Phase 1Seed / early-stageWarsawAI-Driven Drug Discovery
Focus / modality
AI genome interpretation
Lead asset
Whole-genome AI reports
Type
Platform
Indication
Consumer & clinical genomics
Stage
Phase 1
HQ
Warsaw
Capital tier
Seed / early-stage
Backing
VC

Overview

AI platform translating whole-genome data into health and disease-risk insights for consumers and clinicians.

What they do

Imagene.me is a Polish personalised-genomics company that uses artificial intelligence to translate whole-genome sequencing data into actionable health and disease-risk insights. It serves both consumers and clinicians, and offers partners in the health and prevention sectors tools to embed genomic analysis into their own products and services.

Lead program & status

The company's core platform pairs an expert-curated knowledge base with AI to generate personalised health predictions and recommendations, with an ambition to build an AI-driven health assistant supporting patients and medical professionals in real time. As of late 2024, Imagene.me raised investment from ABAN.VC and the NCBR Investment Fund to fund international expansion and scale its own products while supporting B2B partners adopting genomic solutions. Its stated mission is to become a leader in genomics-based preventive healthcare.

Why it matters

Whole-genome data is vast and hard to interpret. By automating that interpretation, Imagene.me aims to make genome-guided prevention practical at scale rather than confined to specialist clinics, positioning Poland in the growing consumer and clinical genomics market.

FAQ

What does Imagene.me do with genome data?
It uses AI to interpret whole-genome sequencing data and turn it into personalised health and disease-risk insights for consumers and clinicians.
Who has invested in Imagene.me?
In late 2024 it secured investment from ABAN.VC and the NCBR Investment Fund to support international expansion.
Is Imagene.me only for consumers?
No. It serves consumers and clinicians and also provides B2B tools so health and prevention partners can integrate genomic analysis.

Technology

Imagene.me works in AI-Driven Drug Discovery — Compressing years of trial-and-error chemistry into months of computation.

Read the AI-Driven Drug Discovery brief →

Related companies

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

No spam · ~1–2 emails/month · unsubscribe anytime.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.